NightHawk Biosciences Inc (NHWK)

[dia76ca]

Yes the two companies technologies complement each other.

Heat Biologics and OncoSec Present Data at the American Conference for Cancer Research (AACR) Annual Meeting

Preclinical findings demonstrate that intratumoral electroporation activate tumor neoantigen-specific immune responses
DURHAM, N.C., April 18, 2016 (GLOBE NEWSWIRE)

-- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer, announced that preclinical data from its collaboration with OncoSec Medical Incorporated (“OncoSec”) focused on evaluating the combination of immunotherapy platforms were presented yesterday at the American Conference for Cancer Research (AACR) Annual Meeting (www.aacr.org).  
In the poster entitled “In vivo intra-tumoral electroporation of gp96-Ig/Fc-OX40L stimulates CD8+ T cell cross-priming to tumor specific neoantigens” (Abstract #567), researchers concluded that combining Heat’s ComPACT vaccine with OncoSec’s intratumoral DNA electroporation delivery platform stimulated an expansion of neoantigen-specific CD8+ T cells, leading to a regression in both treated and untreated cancer lesions in two mouse studies (melanoma and colorectal cancer).  Heat and OncoSec announced their collaboration last year to evaluate the preclinical efficacy of delivering Heat’s immunotherapy vaccines via OncoSec’s ImmunoPulse™ platform.
“In this first preclinical study demonstrating the feasibility of electroporating ComPACT DNA plasmids, we saw robust neoantigen T cell response and tumor regression in both treated and untreated tumors, indicating a systemic anti-tumor response that could be reflective of what we might see in metastatic lesions,” said Taylor Schreiber, M.D., Ph.D., Heat’s Chief Scientific Officer.  “We believe that this approach is promising and that further studies are merited, especially as this combination approach has the potential to stimulate shared and private tumor antigens without introducing the complexities associated with personalized therapies.”
“We are excited by our collaboration with Heat and by these initial findings.  The ability of the tumor’s microenvironment to evade immune recognition and remain non-immunogenic is a significant challenge, which we believe needs to be addressed when designing new immuno-therapies,” added Robert H. Pierce, M.D., OncoSec’s Chief Scientific Officer.  “The initial feasibility data between our two platforms are encouraging and we are currently exploring the potential synergy between our platforms with both ComPACT and interleukin-12 expressing plasmids.”